Form 6-K Innate Pharma SA For: Feb 18
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
Date of report: Wednesday February 18, 2026
Commission File Number: 001-39084
Innate Pharma S.A.
(Translation of registrant's name into English)
Innate Pharma S.A.
117 Avenue de Luminy—BP 30191
13009 Marseille, France
+ 33 (0) 4 30 30 30
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ]
EXHIBIT INDEX
Exhibit Description
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
INNATE PHARMA S.A.
Date: Wednesday February 18, 2026 By: /s/ JONATHAN DICKINSON Name: Jonathan Dickinson
Title: Chief Executive Officer
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Qnity to Present at the Wolfe Research Materials of the Future Conference
- New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA
- InvestorNewsBreaks – Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Harnesses AI, Genetics and Epigenetics to Advance Cardiovascular Risk Detection
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
